| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | 0.01 | 1 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | -0.0023 | 1 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0021 | 1 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.0041 | 1 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.0018 | 1 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0017 | 1 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.0077 | 1 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.0017 | 1 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | -0.0011 | 1 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.00085 | 1 |